Literature DB >> 2864260

SCH-23390 antagonism of a D-2 dopamine agonist depends upon catecholaminergic neurons.

G R Breese, R A Mueller.   

Abstract

SCH-23390, a selective D-1 dopamine antagonist, was found to antagonize the locomotor stimulation induced by LY-171555, an action similar to that for haloperidol in control animals. However, this action of SCH-23390 was prevented in rats treated with 6-hydroxydopamine (6-OHDA) or with reserpine plus alpha-methyl-tyrosine pretreatment. These results indicate that the action of SCH-23390 to antagonize D-2 dopamine receptor actions is dependent upon functional catecholamine-containing neurons. In contrast to the lack of action of SCH-23390 to antagonize LY-171555 in 6-OHDA-treated rats, SCH-23390 blocked the locomotor stimulation induced by SKF-39393, a D-1 dopamine agonist, after this treatment. Thus, D-1 dopamine receptors are distinct from D-2 receptor sites and can exhibit a behavior similar to that observed when D-2 receptors are stimulated. These data suggest that D-1 receptor sites modulate D-2 dopamine receptor function through a mechanism dependent upon functionally intact catecholamine-containing neurons.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2864260      PMCID: PMC3056237          DOI: 10.1016/0014-2999(85)90349-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  19 in total

1.  The site and mode of action of ET495 for the mediation of stereotyped behaviour in the rat.

Authors:  B Costall; R J Naylor
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

2.  Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons.

Authors:  G R Breese; T D Traylor
Journal:  J Pharmacol Exp Ther       Date:  1970-09       Impact factor: 4.030

3.  Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile.

Authors:  E K Silbergeld; R F Pfeiffer
Journal:  J Neurochem       Date:  1977-06       Impact factor: 5.372

4.  SCH-23390: a selective D1 dopamine antagonist with potent D2 behavioral actions.

Authors:  R B Mailman; D W Schulz; M H Lewis; L Staples; H Rollema; D L Dehaven
Journal:  Eur J Pharmacol       Date:  1984-05-18       Impact factor: 4.432

5.  Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390.

Authors:  A G Molloy; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Growth and behavioral changes in developing rats treated intracisternally with 6-hydroxydopamine: evidence for involvement of brain dopamine.

Authors:  R D Smith; B R Cooper; G R Breese
Journal:  J Pharmacol Exp Ther       Date:  1973-06       Impact factor: 4.030

7.  Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons.

Authors:  H Corrodi; K Fuxe; T Hökfelt; P Lidbrink; U Ungerstedt
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765

8.  Comparison of tyrosine hydroxylase and dopamine-beta-hydroxylase inhibition with the effects of various 6-hydroxydopamine treatments on d-amphetamine induced motor activity.

Authors:  A S Hollister; G R Breese; B R Cooper
Journal:  Psychopharmacologia       Date:  1974-03-21

9.  Differential inhibition by dopamine D-1 and D-2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions.

Authors:  J Arnt; J Hyttel
Journal:  Eur J Pharmacol       Date:  1984-07-13       Impact factor: 4.432

10.  Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.

Authors:  G R Breese; A A Baumeister; T J McCown; S G Emerick; G D Frye; K Crotty; R A Mueller
Journal:  J Pharmacol Exp Ther       Date:  1984-11       Impact factor: 4.030

View more
  21 in total

1.  Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization.

Authors:  M T Martin-Iverson; S M Stahl; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

2.  Changes in behavioural responses to the combined administration of D1 and D2 dopamine agonists in normosensitive and D1 supersensitive rats.

Authors:  R Dall'Olio; O Gandolfi; A Vaccheri; P Roncada; N Montanaro
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

3.  Apomorphine anorexia: the role of dopamine receptors in the ventral forebrain.

Authors:  A Towell; P Willner; R Muscat
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

4.  Role of dopamine D-1 and D-2 receptor subtypes in mediating dopamine agonist effects on food consumption in rats.

Authors:  M T Martin-Iverson; C T Dourish
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Blockade of 8-OH-DPAT-induced feeding by dopamine antagonists.

Authors:  R Muscat; A M Montgomery; P Willner
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

6.  Antidepressants given repeatedly increase the behavioural effect of dopamine D-2 agonist.

Authors:  J Maj; Z Rogóz; G Skuza; H Sowińska
Journal:  J Neural Transm Gen Sect       Date:  1989

7.  Dopamine D2 agonist-induced behavioural depression is reversed by dopamine D1 agonists.

Authors:  D M Jackson; S B Ross; S R Edwards
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

8.  Antagonism of apomorphine-induced yawning by SCH 23390: evidence against the autoreceptor hypothesis.

Authors:  M Morelli; R Longoni; L Spina; G Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

9.  Relationship between D1 dopamine receptors, adenylate cyclase, and the electrophysiological responses of rat nucleus accumbens neurons.

Authors:  P A Johansen; X T Hu; F J White
Journal:  J Neural Transm Gen Sect       Date:  1991

10.  The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists.

Authors:  W Hauber; M Münkle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.